🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Envafolimab Injection

    The First People's Hospital of Lianyungang

    Gastrointestinal Neoplasms

    phase 2 small molecule active

    1 trial

  2. Erdafitinib Intravesical Delivery System

    Janssen Cilag International NV

    Non-Muscle Invasive Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  3. Etrumadenant

    Arcus Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule completed

    1 trial

  4. Evogliptin

    Samsung Bioepis NL B.V.

    Type2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  5. FCN-437c+Fulvestrant

    The First People's Hospital of Lianyungang

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  6. FOLFOXIRI-based HAIC+Fuquinitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Neoplasms

    phase 2 small molecule completed

    1 trial

  7. Fezolinetant

    Chinese University of Hong Kong

    Vasomotor Symptoms

    phase 2 small molecule active

    1 trial

  8. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  9. Film-coated placebo to match estetrol monohydrate (E4) 20mg tablet

    Estetra SPRL

    postmenopausal women with vasomotor menopausal symptoms

    phase 2 small molecule active

    1 trial

  10. Fruquintinib

    RenJi Hospital

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  11. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  12. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  13. HB-adMSC

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  14. HUMSCs combined with bovine type I collagen

    The First People's Hospital of Lianyungang

    Burn Wounds

    phase 2 other active

    1 trial

  15. Human Umbilical Cord derived MSCs

    CytoMed Therapeutics Ltd

    Lupus Nephritis

    phase 2 mab active

    1 trial

  16. INO-3112 vaccine

    INOVIO PHARMACEUTICALS, INC.

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  17. IVERMECTIN

    The George Institute

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    phase 2 small molecule active

    1 trial

  18. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  19. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  20. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Ichthyosis

    phase 2 small molecule terminated

    1 trial

  21. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

  22. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acneiform Eruptions

    phase 2 mab terminated

    1 trial

  23. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 2 mab completed

    1 trial

  24. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Palmoplantar Pustulosis

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources